Abstract 117P
Background
Radiofrequency ablation (RFA) helps to achieve R0 resection and may provide an alternative treatment for patients with unresectable colorectal liver metastases (CRLM) in combination with surgical resection. However, researches on efficacy and complication risks of hepatectomy combined with intraoperative RFA for multiple colorectal liver metastases (mCRLM) are limited.
Methods
From January 2013 and March 2017, patients who underwent hepatectomy alone (HA cohort) or hepatectomy combined with intraoperative RFA (HIR cohort) for mCRLM were retrospectively identified from Zhongshan Hospital affiliated to Fudan University. The mCRLM patients that were given ‘hepatectomy combined with intraoperative RFA’ were matched with those treated with hepatectomy alone via 1:1 propensity score (PS) matching. Recurrence-free survival (RFS) and overall survival (OS) after the initial hepatectomy were compared.
Results
After PSM, 252 patients were included (126 in each group). The HIR cohort had more grade I complications while no difference in higher grade complications (p = 0.231) and postoperative morbidity(p = 0.534) was detected. Total recurrence which includes intrahepatic and extrahepatic recurrence was no significantly difference in HIR cohort compared to HA cohort (p = 0.320). The median total RFS for HIG and HA was 10.47months and 10.7 months respectively (HR = 1.086 95% CI 0.766-1.540). The median OS for HIG and HA was 43.9 months and 46.1 months respectively (HR = 0.986 95% CI 0.648-1.307).
Conclusions
Hepatectomy combined with intraoperative RFA can be safely performed in mCRLM patients without an increased severe risk in the procedure and is representing a beneficial treatment to otherwise inoperable patients. The outcome of hepatectomy combined with intraoperative RFA is even comparable to hepatectomy alone after propensity score matching.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract